Development and preliminary validation of a predictive model for IgA nephropathy progression

建立并初步验证IgA肾病进展预测模型

阅读:3

Abstract

IgA nephropathy (IgAN), the most common primary glomerular disease worldwide, poses challenges in predicting progression at diagnosis-particularly in primary care. This study developed and validated a model to estimate 5-year renal survival and support early risk stratification for personalized management. A total of 1135 patients with biopsy-confirmed IgAN from Hangzhou Hospital of Traditional Chinese Medicine (2014-2017) were retrospectively enrolled and randomly assigned to training and internal validation cohorts in a 7:3 ratio. An external validation cohort comprising 352 patients was obtained from three independent centers (2015-2020). To identify robust prognostic variables, 1000 bootstrap samples were generated from the training set, each subjected to tenfold cross-validation to determine the optimal regularization parameter (λ) for the LASSO-Cox model. Variables with non-zero coefficients were recorded across iterations, and the five most frequently selected were used to construct both the XGBoost survival model and a corresponding nomogram. Model performance was evaluated through discrimination, calibration, and clinical utility using ROC curves, Brier scores, calibration curve and decision curve analysis. The area under the curve (AUC) of the nomogram was 0.951 (95% CI, 0.914-0.988) in the training cohort and 0.927 (95% CI, 0.877-0.978) in the internal validation cohort. In the external validation cohort, the AUC was 0.913 (95% CI, 0.870-0.955). The Brier scores were 0.029 and 0.045 for the internal and external validation cohorts, respectively. DCA further demonstrated the favorable clinical utility of the nomogram. A clinically practical prognostic model incorporating routine clinical and pathological features was developed to estimate 5-year renal survival in patients with IgAN. Specifically designed for primary care settings, the model leverages easily accessible data to enable early identification of high-risk individuals and support personalized long-term management. Its simplicity and applicability in resource-limited environments make it a valuable tool for improving outcomes beyond specialist centers.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。